Monoclonal B-cell lymphocytosis (MBL) is a blood disorder defined by a small, clonal expansion of B lymphocytes that lack features of leukemia or lymphoma. It is considered a precursor state to chronic lymphocytic leukemia (CLL) but is not itself a cancer. Most people with MBL remain asymptomatic and never progress to CLL.
Key facts
- Diagnostic threshold: < 5 × 10⁹ clonal B cells/L of blood
- Subtypes: Low-count (< 0.5 × 10⁹/L) and high-count (0.5–5 × 10⁹/L) MBL
- Progression risk: 1–2 % per year for high-count MBL
- Prevalence: Detected in ~5–12 % of adults, increasing with age
- Treatment: No active therapy; regular blood monitoring recommended
Biology and classification
MBL arises when a single abnormal B cell clones itself, creating a population of identical cells with the immunophenotype of CLL (CD5⁺ CD19⁺). Low-count MBL is usually discovered in healthy individuals through sensitive flow cytometry, whereas high-count MBL appears during evaluation of mild lymphocytosis .
Diagnosis
Diagnosis is based on flow cytometric detection of a monoclonal B-cell population in peripheral blood without lymphadenopathy, organ enlargement, cytopenias, or other signs of a B-cell malignancy. Counts above 5 × 10⁹ clonal B cells/L or clinical disease features reclassify the condition as CLL .
Risk factors and genetics
Incidence rises with age and family history of CLL; genetic mutations in driver genes linked to CLL (e.g., TP53, NOTCH1) have been identified in some MBL cases, indicating early clonal evolution . Chronic infections and male sex also correlate with higher prevalence .
Clinical course and management
MBL usually remains stable for years. Only a small fraction of high-count cases progress to CLL requiring therapy. Patients are advised to have periodic blood counts and report symptoms such as fatigue, night sweats, or enlarged lymph nodes. Healthy lifestyle and vaccination against common infections are encouraged .
Importance
MBL represents an early stage in B-cell clonal expansion and a key model for studying the development of CLL and related malignancies. Its recognition helps avoid unnecessary anxiety or treatment while enabling targeted monitoring for those at increased risk.